ClinicalTrials.gg
Active, not recruitingNCT06981091Updated Sep 25, 2026

A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis

A Phase 2 interventional study of XH-S004 20 mg and XH-S004 40 mg in Non-Cystic Fibrosis Bronchiectasis, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

Updated Sep 25, 2026Now Active, not recruitingStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 84 studies in Bronchiectasis with a site in China — 35 open to participants now, 38 under way, 4 of them phase 3. Bronchiectasis · China.

Enrollment
13th of 50
234 · median 120
Started
2025
with 15 others
Phase 2
10 of 84
5 open now
Primary completion
2027-01
later than 16 of 37 live
Registered
63rd of 84
by date

Among the 84 studies in Bronchiectasis with a site in China, this one is the 13th largest by enrollment of the 50 interventional ones that give a count, is one of 16 that started in 2025, is one of 10 in phase 2, reaches primary completion later than 16 of the 37 other live ones, and was the 63rd registered.

Bronchiectasis

405 studies on the registry are indexed under Bronchiectasis; 126 are open to participants now.

Browse Bronchiectasis studies →

Open to participants now

35 of the 84 studies in Bronchiectasis with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 94 Bronchiectasis studies recruiting now, 51 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 13 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Bronchiectasis with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to find out if XH-S004 can reduce pulmanary exacerbation over a 24-week treatment duration in participants with non-cystic fibrosis bronchiectasis.

Read the detailed description

This study is a multicenter, double-blind, placebo-controlled, parallel-group study conducted in china, aimed at evaluating the efficacy, safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of XH-S004 administered once daily for 24 weeks in participants with non-cystic fibrosis bronchiectasis (NCFBE).

This study plans to enroll 231 patients with bronchiectasis. Patients who sign the informed consent form will be screened according to the enrollment criteria, and randomly divided into 3 groups. Participants in groups 1 and 2 will receive different doses of XH-S004. Participants in group 3 will receive placebo.

03

Conditions studied

  • Non-Cystic Fibrosis Bronchiectasis

Keywords

  • Bronchiectasis
  • Active neutrophil elastase
  • Fibrosis
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand the procedures and methods of this trial and sign a written form;
  2. Male or female paticipants aged 18-85 years (inclusive) ;
  3. Chest HRCT shows bronchiectasis affecting one or more lobes, and the condition is clinically diagnosed as non-cystic fibrosis bronchiectasis (clinical manifestations include chronic cough, significant productive cough, and/or intermittent hemoptysis, with or without varying degrees of polypnoea and other symptoms);
  4. Based on medical history and the determination of the investigator , participants have at least 2 documented pulmonary exacerbations in the past 12 months before Screening;
  5. Are current sputum producers with a history of chronic expectoration and able to provide a spontaneous sputum sample at screening visit (as described by the patient) ;
  6. The (BMI) is ≥18 kg/m2 at screening;
  7. Participants must ensure and agree that from 28 days prior to signing the informed consent form to 28 days after the final administration, women of , male participants, and their partners will use effective methods other than oral drugs (e.g., condoms or intra-uterine contraceptive devices) and will not donate sperm or eggs during this period

Exclusion criteria

Exclusion Criteria:

  1. Have a primary diagnosis of (COPD) or asthma
  2. Have bronchiectasis due to cystic fibrosis (CF), hypogammaglobulinemia, common variable immunodeficiency, or alpha1-antitrypsin deficiency
  3. Are currently being treated for a nontuberculous mycobacterial lung infection, allergic bronchopulmonary aspergillosis, or tuberculosis
  4. Have any acute infections, (including respiratory infections)
  5. Patients who have previously received therapy with DPP1 inhibitors of the same class
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
234 participants (actual)

Study arms

  • Experimental
    Arm 1: Participant Group

    Participants received XH-S004 20 mg once daily (QD) , for 24 weeks.

    Other: XH-S004 20 mg

  • Experimental
    Arm 2: Participant Group

    Participants received XH-S004 40 mg once daily (QD) , for 24 weeks.

    Other: XH-S004 40 mg

  • Placebo comparator
    Arm 3: Participant Group

    Participants received the matching placebo once daily (QD) , for 24 weeks.

    Other: Placebo

Interventions

  • OtherXH-S004 20 mg

    Administered once per day for 24 weeks.

  • OtherXH-S004 40 mg

    Administered once per day for 24 weeks.

  • OtherPlacebo

    Administered once per day for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Time to the First Pulmonary Exacerbation Over 24-Week Treatment Period

    Time to first pulmonary exacerbation was calculated as the number of days from the date of randomization to the date of first documentation of an exacerbation. Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics (EMBARC guideline) : 1. Increased cough 2. Increased sputum volume 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis.

    Time frame: Baseline (Day 1) to Week 24

Secondary outcomes

  1. Incidence of pulmonary exacerbation as defined by EMBARC over 24-week treatment period.

    Time to first pulmonary exacerbation was calculated as the number of days from the date of randomization to the date of first documentation of an exacerbation. Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics (EMBARC guideline) : 1. Increased cough 2. Increased sputum volume 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis.

    Time frame: Baseline (Day 1) to Week 24

  2. Incidence of Pulmonary exacerbation as defined by investigators over 24-week treatment period.

    The definition of pulmonary exacerbation determined by investigator was defined as: Compared with previous symptoms, patient's current symptoms have worsened but not meet the EMBARC guideline-defined criteria for pulmonary exacerbation . However, the invetigator will have determined that oral/IV antibiotic therapy is required.

    Time frame: Baseline (Day 1) to Week 24

  3. Change from baseline in forced expiratory volume in 1 second (FEV1) in pulmonary function test at week 24 after first drug administration.

    FEV1 was used to assess lung function and is the maximum amount of air that can be forced out in one second after taking a deep breath.

    Time frame: At baseline and at week 24

  4. Change from baseline in Quality of Life Questionnaire - Bronchiectasis (QOLB) respiratory symptoms domain score at week 24 after first drug administration;

    The QOL-B is a validated, self-administered patient reported outcome (PRO) that assesses symptoms, functioning, and health-related (HR) QOL for participants with non-cystic fibrosis bronchiectasis (NCFBE). The QOL-B contains 37 items in 8 domains (Respiratory Symptoms, Physical Functioning, Role Functioning, Emotional Functioning, Social Functioning, Vitality, Health Perceptions and Treatment Burden). Each of the 37 items is scored from 1 to 4, and each of the 8 domains scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning and HR QoL. A positive change from Baseline indicates improvement in symptoms. For this outcome measure, change in the respiratory symptoms domain score from Baseline was reported.

    Time frame: At baseline and at week 24

  5. Change From Baseline in Concentration of Active Neutrophil Elastase (NE) in Sputum

    The concentration of active NE in sputum, was measured by the difference between the pre-treatment concentration, on-treatment concentration and post-treatment concentration. In bronchiectasis, activation of neutrophils in the airway leads to release of NE which leads to damaged airway walls, mucus hypersecretion, exacerbated inflammation, which in turn affects neutrophil and macrophage functions, increasing the risk of infection. Negative change from Baseline indicates improvement.

    Time frame: Baseline (Day 1) to Week 24

07

Study locations

1 site
  • Huadong Hospital Affiliated to fudan univercity
    Shanghai, Shanghai Municipality 200040, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jan 2027, 19 months after the start.

Of 24 phase 2 interventional studies under Bronchiectasis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's planned 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2025
First posted
May 20, 2025
StartActual
May 30, 2025
Primary completionEst.
Jan 8, 2027
CompletionEst.
Apr 28, 2027
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Sep 25, 2026
Sites
1 site added, 1 site removed
Show site
  • Huadong Hospital Affiliated to fudan univercity · Shanghai, China
Show 1 removed
  • Huadong Hospital Affiliated to fudan univercity · Shanghai, China
Sep 25, 2026
Start date
May 16, 2025→May 30, 2025 (actual)
Sep 25, 2026
Enrollment
231 (estimated)→234 (actual)
Sep 25, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionChange from baseline in Quality of Life Questionnaire - Bronchiectasis (QOLB) respiratory symptoms domain score at week 24 after first drug administration;: how it is measured was reworded
Sep 25, 2026
Sponsor
S-INFINITY Pharmaceuticals Co., Ltd→Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Not yet recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • Huadong Hospital Affiliated to fudan univercity · Shanghai, China
    Show 1 removed
    • Huadong Hospital Affiliated to fudan univercity · Shanghai, China
    Start date May 16, 2025→May 30, 2025 (now actual)
    Enrollment 231 (estimated)→234 (actual)
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionChange from baseline in Quality of Life Questionnaire - Bronchiectasis (QOLB) respiratory symptoms domain score at week 24 after first drug administration;: how it is measured was reworded
    Sponsor S-INFINITY Pharmaceuticals Co., Ltd→Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
    + 4 other changes: index terms, identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06981091
Responsible party
Sponsor
First posted
May 20, 2025
Start date
May 30, 2025
Primary completion
Jan 8, 2027 (estimated)
Completion
Apr 28, 2027 (estimated)
Last update
Sep 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion